alunbrig
takeda pharma a/s - brigatinib - krabbamein, lungnakrabbamein - Æxlishemjandi lyf - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.
dasatinib krka filmuhúðuð tafla 70 mg
krka d.d. novo mesto* - dasatinibum inn - filmuhúðuð tafla - 70 mg
erlotinib wh filmuhúðuð tafla 100 mg
williams & halls ehf. - erlotinibum hýdróklóríð - filmuhúðuð tafla - 100 mg
erlotinib wh filmuhúðuð tafla 150 mg
williams & halls ehf. - erlotinibum hýdróklóríð - filmuhúðuð tafla - 150 mg